肥満・インスリン抵抗性を示す2型糖尿病患者におけるメトホルミン使用に関する研究

概要

論文の詳細を見る
To examine the effectiveness of metformin (Met) in combination with sulfonylurea (SU) or α-glycosidase inhibitor (α-GI) or both SU and α-GI, 120 type 2 diabetes mellitus with obesity and insulin resistance have been included in a prospective study at both outpatient and inpatient clinics at Tokyo Metropolitan Futyu Hospital. Met treatment of 500mg or 750mg/day was administered in all groups. A significant reduction in the hemoglobin A_1c levels along with improvements in the insulin resistant index were observed for the α-GI+Met group after 6 months, and also for the Met monotherapy, SU+Met and SU+α-GI+Met groups after 12months. Only 7 patients showed transitional adoversed effects such as gastrointestinal symptoms (nausea and vomiting), but no patient experienced lactic acidosis. In conclusion, 1) as indicated in the Japanese medication insert, the effectiveness of Met in combination use with SU was confirmed in patients previously found to be poorly controlled with SU monotherapy. In addition, the effectiveness of the non-indicated use of Met was also suggested under the following two conditions: 2) Met monotherapy in type 2 diabetes mellitus who did not respond to diet therapy was also effective; 3) The addition of Met is also effective in patients whose glucose levels were previously poorly controlled with both α-GI and α-GI+SU. Further study is necessary to increase the adoptions for Japanese medication inserts for type 2 diabetes mellitus patients.
日本医療薬学会の論文
2002-02-10

肥満・インスリン抵抗性を示す2型糖尿病患者におけるメトホルミン使用に関する研究

スポンサーリンク

概要

著者

関連論文

スポンサーリンク